{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:48:48Z","timestamp":1791265728845,"version":"4.1.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.ygyno.2019.02.018","type":"journal-article","created":{"date-parts":[[2019,3,2]],"date-time":"2019-03-02T01:20:29Z","timestamp":1551489629000},"page":"238-241","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Should mucosal bowel invasion in ovarian cancer be assigned to FIGO stage IV disease?"],"prefix":"10.1016","volume":"153","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5379-7813","authenticated-orcid":false,"given":"Ismail","family":"Mert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanika","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diogo","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajue","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela E.","family":"McGree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Cliby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2019.02.018_bb0005","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2019.02.018_bb0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2017.02.023","article-title":"Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?","volume":"145","author":"Sioulas","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.02.018_bb0020","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0090-8258(92)90100-W","article-title":"The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a gynecologic oncology group study","volume":"47","author":"Hoskins","year":"1992","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.02.018_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","article-title":"Staging classification for cancer of the ovary, fallopian tube, and peritoneum","volume":"124","author":"Prat","year":"2014","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.ygyno.2019.02.018_bb0030","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.ygyno.2006.06.004","article-title":"The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns","volume":"103","author":"Park","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.02.018_bb0035","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1477-7819-11-64","article-title":"Depth of colorectal-wall invasion and lymph-node involvement as major outcome factors influencing surgical strategy in patients with advanced and recurrent ovarian cancer with diffuse peritoneal metastases","volume":"11","author":"Di Giorgio","year":"2013","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2019.02.018_bb0040","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ygyno.2017.09.021","article-title":"Intraperitoneal disease dissemination patterns are associated with residual disease, extent of surgery, and molecular subtypes in advanced ovarian cancer","volume":"147","author":"Torres","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"676","key":"10.1016\/j.ygyno.2019.02.018_bb0045","first-page":"e1","article-title":"Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer","volume":"197","author":"Aletti","year":"2007","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2019.02.018_bb0050","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ygyno.2017.01.029","article-title":"Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible","volume":"145","author":"Wallace","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.02.018_bb0060","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ygyno.2006.03.051","article-title":"What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?","volume":"103","author":"Chi","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.02.018_bb0065","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ygyno.2018.06.002","article-title":"Factors that influence survival in high-grade serous ovarian cancer: a complex relationship between molecular subtype, disease dissemination, and operability","volume":"150","author":"Torres","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.02.018_bb0070","first-page":"106","article-title":"Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer","author":"Konecny","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2019.02.018_bb0075","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1158\/1078-0432.CCR-17-0246","article-title":"Pooled clustering of high-grade serous ovarian cancer gene expression leads to novel consensus subtypes associated with survival and surgical outcomes","volume":"23","author":"Wang","year":"2017","journal-title":"Clin. Cancer Res."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819301283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819301283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:45:33Z","timestamp":1758771933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825819301283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0090825819301283"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.02.018","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Should mucosal bowel invasion in ovarian cancer be assigned to FIGO stage IV disease?","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}